Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

Genevieve M. Crane, Helen Powell, Rumen Kostadinov, Patrick Tim Rocafort, Dena E. Rifkin, Peter C. Burger, Richard F Ambinder, Lode Swinnen, Michael J Borowitz, Amy S Duffield

Research output: Contribution to journalArticle

Abstract

Immunosuppression for solid organ transplantation increases lymphoproliferative disease risk. While central nervous system (CNS) involvement is more rare, we noticed an increase in primary CNS (PCNS) disease. To investigate a potential association with the immunosuppressive regimen we identified all post-transplant lymphoproliferative disease (PTLD) cases diagnosed over a 28-year period at our institution (174 total, 29 PCNS) and all similar cases recorded in a United Network for Organ Sharing-Organ Procurement and Transplant Network (UNOS-OPTN) data file. While no PCNS cases were diagnosed at our institution between 1986 and 1997, they comprised 37% of PTLD cases diagnosed from 2011-2014. PCNS disease was more often associated with renal vs. other organ transplant, Epstein-Barr virus, large B-cell morphology and mycophenolate mofetil (MMF) as compared to PTLD that did not involve the CNS. Calcineurin inhibitors were protective against PCNS disease when given alone or in combination with MMF. A multivariate analysis of a larger UNOS-OPTN dataset confirmed these findings, where both MMF and lack of calcineurin inhibitor usage were independently associated with risk for development of PCNS PTLD. These findings have significant implications for the transplant community, particularly given the introduction of new regimens lacking calcineurin inhibitors. Further investigation into these associations is warranted.

Original languageEnglish (US)
Pages (from-to)33849-33866
Number of pages18
JournalOncotarget
Volume6
Issue number32
DOIs
StatePublished - 2015

Fingerprint

Central Nervous System Diseases
Transplants
Mycophenolic Acid
Tissue and Organ Procurement
Central Nervous System
Calcineurin Inhibitors
Information Storage and Retrieval
Organ Transplantation
Immunosuppressive Agents
Human Herpesvirus 4
Immunosuppression
B-Lymphocytes
Multivariate Analysis
Kidney

Keywords

  • Calcineurin inhibitors
  • Epstein-Barr virus
  • Mycophenolate mofetil
  • Post-transplant lymphoproliferative disorder
  • Primary central nervous system lymphoma

ASJC Scopus subject areas

  • Oncology

Cite this

Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. / Crane, Genevieve M.; Powell, Helen; Kostadinov, Rumen; Rocafort, Patrick Tim; Rifkin, Dena E.; Burger, Peter C.; Ambinder, Richard F; Swinnen, Lode; Borowitz, Michael J; Duffield, Amy S.

In: Oncotarget, Vol. 6, No. 32, 2015, p. 33849-33866.

Research output: Contribution to journalArticle

Crane, Genevieve M. ; Powell, Helen ; Kostadinov, Rumen ; Rocafort, Patrick Tim ; Rifkin, Dena E. ; Burger, Peter C. ; Ambinder, Richard F ; Swinnen, Lode ; Borowitz, Michael J ; Duffield, Amy S. / Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. In: Oncotarget. 2015 ; Vol. 6, No. 32. pp. 33849-33866.
@article{78578a9db3204612b3e77ca32113d169,
title = "Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage",
abstract = "Immunosuppression for solid organ transplantation increases lymphoproliferative disease risk. While central nervous system (CNS) involvement is more rare, we noticed an increase in primary CNS (PCNS) disease. To investigate a potential association with the immunosuppressive regimen we identified all post-transplant lymphoproliferative disease (PTLD) cases diagnosed over a 28-year period at our institution (174 total, 29 PCNS) and all similar cases recorded in a United Network for Organ Sharing-Organ Procurement and Transplant Network (UNOS-OPTN) data file. While no PCNS cases were diagnosed at our institution between 1986 and 1997, they comprised 37{\%} of PTLD cases diagnosed from 2011-2014. PCNS disease was more often associated with renal vs. other organ transplant, Epstein-Barr virus, large B-cell morphology and mycophenolate mofetil (MMF) as compared to PTLD that did not involve the CNS. Calcineurin inhibitors were protective against PCNS disease when given alone or in combination with MMF. A multivariate analysis of a larger UNOS-OPTN dataset confirmed these findings, where both MMF and lack of calcineurin inhibitor usage were independently associated with risk for development of PCNS PTLD. These findings have significant implications for the transplant community, particularly given the introduction of new regimens lacking calcineurin inhibitors. Further investigation into these associations is warranted.",
keywords = "Calcineurin inhibitors, Epstein-Barr virus, Mycophenolate mofetil, Post-transplant lymphoproliferative disorder, Primary central nervous system lymphoma",
author = "Crane, {Genevieve M.} and Helen Powell and Rumen Kostadinov and Rocafort, {Patrick Tim} and Rifkin, {Dena E.} and Burger, {Peter C.} and Ambinder, {Richard F} and Lode Swinnen and Borowitz, {Michael J} and Duffield, {Amy S}",
year = "2015",
doi = "10.18632/oncotarget.5292",
language = "English (US)",
volume = "6",
pages = "33849--33866",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

AU - Crane, Genevieve M.

AU - Powell, Helen

AU - Kostadinov, Rumen

AU - Rocafort, Patrick Tim

AU - Rifkin, Dena E.

AU - Burger, Peter C.

AU - Ambinder, Richard F

AU - Swinnen, Lode

AU - Borowitz, Michael J

AU - Duffield, Amy S

PY - 2015

Y1 - 2015

N2 - Immunosuppression for solid organ transplantation increases lymphoproliferative disease risk. While central nervous system (CNS) involvement is more rare, we noticed an increase in primary CNS (PCNS) disease. To investigate a potential association with the immunosuppressive regimen we identified all post-transplant lymphoproliferative disease (PTLD) cases diagnosed over a 28-year period at our institution (174 total, 29 PCNS) and all similar cases recorded in a United Network for Organ Sharing-Organ Procurement and Transplant Network (UNOS-OPTN) data file. While no PCNS cases were diagnosed at our institution between 1986 and 1997, they comprised 37% of PTLD cases diagnosed from 2011-2014. PCNS disease was more often associated with renal vs. other organ transplant, Epstein-Barr virus, large B-cell morphology and mycophenolate mofetil (MMF) as compared to PTLD that did not involve the CNS. Calcineurin inhibitors were protective against PCNS disease when given alone or in combination with MMF. A multivariate analysis of a larger UNOS-OPTN dataset confirmed these findings, where both MMF and lack of calcineurin inhibitor usage were independently associated with risk for development of PCNS PTLD. These findings have significant implications for the transplant community, particularly given the introduction of new regimens lacking calcineurin inhibitors. Further investigation into these associations is warranted.

AB - Immunosuppression for solid organ transplantation increases lymphoproliferative disease risk. While central nervous system (CNS) involvement is more rare, we noticed an increase in primary CNS (PCNS) disease. To investigate a potential association with the immunosuppressive regimen we identified all post-transplant lymphoproliferative disease (PTLD) cases diagnosed over a 28-year period at our institution (174 total, 29 PCNS) and all similar cases recorded in a United Network for Organ Sharing-Organ Procurement and Transplant Network (UNOS-OPTN) data file. While no PCNS cases were diagnosed at our institution between 1986 and 1997, they comprised 37% of PTLD cases diagnosed from 2011-2014. PCNS disease was more often associated with renal vs. other organ transplant, Epstein-Barr virus, large B-cell morphology and mycophenolate mofetil (MMF) as compared to PTLD that did not involve the CNS. Calcineurin inhibitors were protective against PCNS disease when given alone or in combination with MMF. A multivariate analysis of a larger UNOS-OPTN dataset confirmed these findings, where both MMF and lack of calcineurin inhibitor usage were independently associated with risk for development of PCNS PTLD. These findings have significant implications for the transplant community, particularly given the introduction of new regimens lacking calcineurin inhibitors. Further investigation into these associations is warranted.

KW - Calcineurin inhibitors

KW - Epstein-Barr virus

KW - Mycophenolate mofetil

KW - Post-transplant lymphoproliferative disorder

KW - Primary central nervous system lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84946042329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946042329&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5292

DO - 10.18632/oncotarget.5292

M3 - Article

C2 - 26460822

AN - SCOPUS:84946042329

VL - 6

SP - 33849

EP - 33866

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -